These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 27699999)
1. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Reid RM; Baran A; Friedberg JW; Phillips GL; Liesveld JL; Becker MW; Wedow L; Barr PM; Milner LA Cancer Med; 2016 Nov; 5(11):3059-3067. PubMed ID: 27699999 [TBL] [Abstract][Full Text] [Related]
2. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Isidori A; Christofides A; Visani G Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412 [TBL] [Abstract][Full Text] [Related]
3. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642 [TBL] [Abstract][Full Text] [Related]
4. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma. Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909 [TBL] [Abstract][Full Text] [Related]
5. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401 [TBL] [Abstract][Full Text] [Related]
6. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637 [TBL] [Abstract][Full Text] [Related]
7. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma. Grisariu S; Shapira MY; Or R; Avni B Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148 [TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F; Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196 [TBL] [Abstract][Full Text] [Related]
9. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation. Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959 [TBL] [Abstract][Full Text] [Related]
10. Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning. Lasica M; Taylor E; Bhattacharyya P; Bennett A; Cooke RE; Stern C; Agresta F; Ayton R; Grigg A Eur J Haematol; 2016 Oct; 97(4):348-52. PubMed ID: 26773518 [TBL] [Abstract][Full Text] [Related]
11. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714 [TBL] [Abstract][Full Text] [Related]
12. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848 [TBL] [Abstract][Full Text] [Related]
13. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001 [TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029 [TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541 [TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Martin N; Borchiellini D; Coso D; Gastaud L; Boscagli A; Saudes L; Re D; Gutnecht J; Garnier G; Petit E; Barriere J; Naman H; Rossignol B; Thyss A; Peyrade F Leuk Lymphoma; 2015; 56(8):2379-87. PubMed ID: 25563428 [TBL] [Abstract][Full Text] [Related]
17. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]
18. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762 [TBL] [Abstract][Full Text] [Related]
19. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Singer S; Dean R; Zhao Q; Sharma N; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA Biol Blood Marrow Transplant; 2019 Jun; 25(6):1107-1115. PubMed ID: 30716453 [TBL] [Abstract][Full Text] [Related]
20. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]